Table 3.
Antibiotic therapies and outcomes.
| Antibiotic Therapies and Outcome | Value (n = 19) |
|---|---|
| Empiric therapy, n (%) | 14 (73.7) |
| Appropriate empiric therapy, n (%) | 2 (10.5) |
| Start of a target therapy >48 h, n (%) | 15 (78.9) |
| Target monotherapy, n (%) | 12 (63.2) |
| Colistin | 6 (31.2) |
| Meropenem | 3 (15.8) |
| Piperacillin/tazobactam | 1 (5.3) |
| Amikacin | 1 (5.3) |
| Ceftazidime/avibactam | 1 (5.3) |
| Target Combination therapy, n (%) | 7 (36.8) |
| Ceftazidime/Avibactam + Colistin | 2 (15.4) |
| Colistin + Meropenem | 2 (15.4) |
| Ceftolozane/tazobactam + Amikacin | 1 (5.3) |
| Ceftazidime/avibactam + Amikacin | 1 (5.3) |
| Colistin + Piperacillin/tazobactam | 1 (5.3) |
| Source control, n (%) | 8 (42.1) |
| Length of therapy in days, median (IQR) | 10 (7–14) |
| Death (30 days), n (%) | 2 (15.4) |
| Clinical success, n (%) | 17 (89.5) |
| Microbiological failure, n/patients evaluated (%) | 3/13 (23.1) |
| Recurrent infection, n (%) | 1 (5.3) |